It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Adiponectin is a secretory protein, primarily produced in adipocytes. However, low but detectable expression of adiponectin can be observed in cell types beyond adipocytes, particularly in kidney tubular cells, but its local renal role is unknown. We assessed the impact of renal adiponectin by utilizing male inducible kidney tubular cell-specific adiponectin overexpression or knockout mice. Kidney-specific adiponectin overexpression induces a doubling of phosphoenolpyruvate carboxylase expression and enhanced pyruvate-mediated glucose production, tricarboxylic acid cycle intermediates and an upregulation of fatty acid oxidation (FAO). Inhibition of FAO reduces the adiponectin-induced enhancement of glucose production, highlighting the role of FAO in the induction of renal gluconeogenesis. In contrast, mice lacking adiponectin in the kidney exhibit enhanced glucose tolerance, lower utilization and greater accumulation of lipid species. Hence, renal adiponectin is an inducer of gluconeogenesis by driving enhanced local FAO and further underlines the important systemic contribution of renal gluconeogenesis.
Adiponectin is a widely studied secretory protein produced by adipocytes. Here, the authors show that adiponectin is also expressed in the kidney where it is a major driver of fatty acid oxidation, from which the kidney derives energy for gluconeogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 The University of Texas Southwestern Medical Center, Touchstone Diabetes Center, Dallas, US (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
2 Texas A&M University College of Medicine, Division of Lymphatic Biology, Department of Medical Physiology, Bryan, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082)
3 University of Texas Southwestern Medical Center, Center for Human Nutrition, Dallas, US (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
4 University of Pennsylvania Perelman School of Medicine, Renal, Electrolyte, and Hypertension Division, Department of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Universitätsmedizin Berlin, Department of Nephrology and Medical Intensive Care, Charité, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin Institute of Health at Charité, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
5 The University of Texas Southwestern Medical Center, Touchstone Diabetes Center, Dallas, US (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Health Science Center at Houston, Department of Anesthesiology, Critical Care and Pain Medicine, Houston, TX, USA (GRID:grid.267308.8) (ISNI:0000 0000 9206 2401)
6 University of Texas Southwestern Medical Center, Center for Hypothalamic Research, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
7 Solutions COE, Analytical & Measuring Instruments Division, Shimadzu Corporation, Kyoto, Japan (GRID:grid.274249.e) (ISNI:0000 0004 0571 0853)
8 University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
9 University of Texas Southwestern Medical Center, Departments of Cell Biology and Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
10 University of Texas Southwestern Medical Center, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); University of Texas Southwestern Medical Center, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
11 University of Pennsylvania Perelman School of Medicine, Renal, Electrolyte, and Hypertension Division, Department of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
12 University of Texas Southwestern Medical Center, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); University of Texas Southwestern Medical Center, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); University of Texas Southwestern Medical Center, Department of Physiology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
13 The University of Texas Southwestern Medical Center, Touchstone Diabetes Center, Dallas, US (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); University of Texas Southwestern Medical Center, Departments of Cell Biology and Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)